Skip to Content
Merck
All Photos(2)

Documents

855810P

Avanti

26:0 Lyso PC

1-hexacosanoyl-2-hydroxy-sn-glycero-3-phosphocholine, powder

Synonym(s):

1-hexacosanoyl-sn-glycero-3-phosphocholine; PC(26:0/0:0)

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C34H70NO7P
CAS Number:
1213783-80-2
Molecular Weight:
635.90
UNSPSC Code:
51191904
NACRES:
NA.25

Assay

>99% (LPC; may contain up to 10% of the 2-LPC isomer, TLC)

form

powder

packaging

pkg of 1 × 10 mg (855810P-10mg)
pkg of 1 × 25 mg (855810P-25mg)
pkg of 1 × 5 mg (855810P-5mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand 855810P

shipped in

dry ice

storage temp.

−20°C

General description

Lysophosphatidylcholine (LPC) is a bioactive proinflammatory lipid, which has a choline group at its polar head. It is produced by pathological response.

Application

26:0 Lyso PC has been used as an internal standard for C26:0-lysophosphatidylcholine (LPC) extraction.

Biochem/physiol Actions

Lysophosphatidylcholine (LPC) induces many second messengers including, protein kinase C, extracellular-signal-regulated kinases and protein tyrosine kinases. It alters various biological functions in different cell types, including endothelial cells, smooth muscle cells, monocytes, macrophages and T-cells. LPC is linked to atherosclerosis and inflammatory diseases.

Packaging

5 mL Amber Glass Screw Cap Vial (855810P-10mg)
5 mL Amber Glass Screw Cap Vial (855810P-25mg)
5 mL Amber Glass Screw Cap Vial (855810P-5mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Storage Class Code

11 - Combustible Solids

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Xinying Hong et al.
Genetics in medicine : official journal of the American College of Medical Genetics (2020-04-21)
To develop a multiplexed assay for the newborn screening of lysosomal storage disorders and additional inborn errors in a flexible, comprehensive, and affordable manner to keep up with the expansion of the newborn screening panel. Ultraperformance liquid chromatography-tandem mass spectrometry
A thyroid hormone-based strategy for correcting the biochemical abnormality in X-linked adrenoleukodystrophy
Hartley MD, et al.
Endocrinology, 158(5), 1328-1338 (2017)
Role of lysophosphatidylcholine (LPC) in atherosclerosis
Matsumoto T, et al.
Current Medicinal Chemistry, 14(30), 3209-3220 (2007)
Analysis of phospholipid species in rat peritoneal surface layer by liquid chromatography/electrospray ionization ion-trap mass spectrometry
Gao F, et al.
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1761(7), 667-676 (2006)
Kelsey B Law et al.
Autophagy, 13(5), 868-884 (2017-05-20)
Peroxisome biogenesis disorders (PBDs) are metabolic disorders caused by the loss of peroxisomes. The majority of PBDs result from mutation in one of 3 genes that encode for the peroxisomal AAA ATPase complex (AAA-complex) required for cycling PEX5 for peroxisomal
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service